Humana Inc. $HUM Stock Position Decreased by Gradient Investments LLC

Key Points

• Gradient Investments reduced its Humana position by 31.3% in the second quarter, selling 6,112 shares and retaining 13,408 shares valued at approximately $5.33 million. Institutional investors collectively own 92.38% of Humana.
• Humana shares opened at $384.44, up 4.7%, while the company reported quarterly EPS of $7.61, beating estimates by $0.34. Revenue rose 26.2% year over year to $40.89 billion.
• Analyst sentiment remains broadly positive, with MarketBeat assigning Humana a “Moderate Buy” consensus rating and an average price target of $391.87; Bank of America upgraded the stock to “buy” with a $500 target.

Gradient Investments LLC trimmed its position in shares of Humana Inc. (NYSE:HUM - Free Report) by 31.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,408 shares of the insurance provider's stock after selling 6,112 shares during the quarter. Gradient Investments LLC's holdings in Humana were worth $5,326,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Montag A & Associates Inc. increased its holdings in Humana by 1,880.0% in the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider's stock worth $25,000 after buying an additional 94 shares during the last quarter. Fideuram Asset Management Ireland dac acquired a new stake in Humana in the fourth quarter valued at approximately $27,000. Reflection Asset Management acquired a new stake in Humana in the fourth quarter valued at approximately $29,000. Global Assets Advisory LLC bought a new stake in Humana in the first quarter worth approximately $38,000. Finally, Larson Financial Group LLC grew its position in Humana by 114.1% in the third quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider's stock worth $40,000 after acquiring an additional 81 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Humana Stock Up 4.7%

Shares of HUM stock opened at $384.44 on Friday. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $428.88. The firm has a market cap of $46.16 billion, a PE ratio of 36.37, a price-to-earnings-growth ratio of 2.20 and a beta of 0.72. The stock has a 50 day moving average of $377.18 and a 200-day moving average of $271.65. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.27 by $0.34. Humana had a net margin of 0.88% and a return on equity of 11.20%. The business had revenue of $40.89 billion for the quarter, compared to the consensus estimate of $40.58 billion. During the same quarter last year, the company posted $6.27 earnings per share. Humana's quarterly revenue was up 26.2% on a year-over-year basis. On average, equities analysts predict that Humana Inc. will post 9.08 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on HUM shares. Barclays raised their price target on shares of Humana from $344.00 to $407.00 and gave the company an "equal weight" rating in a report on Friday, July 31st. Truist Financial upped their price objective on shares of Humana from $320.00 to $415.00 and gave the stock a "hold" rating in a report on Tuesday, July 14th. TD Cowen increased their target price on shares of Humana from $350.00 to $370.00 and gave the stock a "hold" rating in a research report on Friday, July 31st. Bank of America upgraded Humana from a "neutral" rating to a "buy" rating and set a $500.00 target price on the stock in a report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. boosted their price target on Humana from $214.00 to $316.00 and gave the stock a "neutral" rating in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $391.87.

About Humana

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source